172 related articles for article (PubMed ID: 11939763)
1. United Kingdom prospective diabetes study: a different perspective.
Kabadi UM
Endocr Pract; 2002; 8(1):61-4. PubMed ID: 11939763
[No Abstract] [Full Text] [Related]
2. A summary of the ADVANCE Trial.
Heller SR;
Diabetes Care; 2009 Nov; 32 Suppl 2(Suppl 2):S357-61. PubMed ID: 19875581
[No Abstract] [Full Text] [Related]
3. Early insulin use in type 2 diabetes: what are the cons?
Chiasson JL
Diabetes Care; 2009 Nov; 32 Suppl 2(Suppl 2):S270-4. PubMed ID: 19875563
[No Abstract] [Full Text] [Related]
4. The UK Prospective Diabetes Study. UK Prospective Diabetes Study Group.
Turner RC; Holman RR
Ann Med; 1996 Oct; 28(5):439-44. PubMed ID: 8949976
[TBL] [Abstract][Full Text] [Related]
5. United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. United Kingdom Prospective Diabetes Study Group.
Ann Intern Med; 1998 Feb; 128(3):165-75. PubMed ID: 9454524
[TBL] [Abstract][Full Text] [Related]
6. Combination therapy with insulin glargine plus metformin but not insulin glargine plus sulfonylurea provides similar glycemic control to triple oral combination therapy in patients with type 2 diabetes uncontrolled with dual oral agent therapy.
Hollander P; Sugimoto D; Vlajnic A; Kilo C
J Diabetes Complications; 2015; 29(8):1266-71. PubMed ID: 26281972
[TBL] [Abstract][Full Text] [Related]
7. Hypoglycemia in Type 2 diabetic patients randomized to and maintained on monotherapy with diet, sulfonylurea, metformin, or insulin for 6 years from diagnosis: UKPDS73.
Wright AD; Cull CA; Macleod KM; Holman RR;
J Diabetes Complications; 2006; 20(6):395-401. PubMed ID: 17070446
[TBL] [Abstract][Full Text] [Related]
8. Oral Hypoglycemic Agents Added to Insulin Monotherapy for Type 2 Diabetes.
Vos RC; Rutten GEHM
JAMA; 2017 Oct; 318(15):1489-1490. PubMed ID: 29049639
[TBL] [Abstract][Full Text] [Related]
9. [Tough glucose reduction necessary in newly diagnosed diabetes].
Rydén M
Lakartidningen; 2010 Nov 10-16; 107(45):2810-4. PubMed ID: 21179867
[No Abstract] [Full Text] [Related]
10. Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas.
Deacon CF; Lebovitz HE
Diabetes Obes Metab; 2016 Apr; 18(4):333-47. PubMed ID: 26597596
[TBL] [Abstract][Full Text] [Related]
11. Importance of glucose control.
Edelman SV
Med Clin North Am; 1998 Jul; 82(4):665-87. PubMed ID: 9706116
[TBL] [Abstract][Full Text] [Related]
12. 10-year follow-up of intensive glucose control in type 2 diabetes.
Holman RR; Paul SK; Bethel MA; Matthews DR; Neil HA
N Engl J Med; 2008 Oct; 359(15):1577-89. PubMed ID: 18784090
[TBL] [Abstract][Full Text] [Related]
13. Monitoring safety and effectiveness in patients receiving metformin.
Choe HM; Cornish L; Townsend K; Jobe J; Mitrovich S
Am J Health Syst Pharm; 2004 Aug; 61(15):1550-1. PubMed ID: 15372824
[No Abstract] [Full Text] [Related]
14. Diabetes specialists keep ACCORD data in perspective.
Traynor K
Am J Health Syst Pharm; 2008 Mar; 65(6):488, 490. PubMed ID: 18319488
[No Abstract] [Full Text] [Related]
15. The cost-effectiveness of dapagliflozin versus sulfonylurea as an add-on to metformin in the treatment of Type 2 diabetes mellitus.
Charokopou M; McEwan P; Lister S; Callan L; Bergenheim K; Tolley K; Postema R; Townsend R; Roudaut M
Diabet Med; 2015 Jul; 32(7):890-8. PubMed ID: 25817050
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of hypoglycemia among a sample of sulfonylurea-treated patients with Type 2 diabetes mellitus in Argentina: The real-life effectiveness and care patterns of diabetes management (RECAP-DM) study.
Gonzalez C; Monti C; Pinzon A; Monsanto H; Ejzykowicz F;
Endocrinol Diabetes Nutr (Engl Ed); 2018 Dec; 65(10):592-602. PubMed ID: 30076124
[TBL] [Abstract][Full Text] [Related]
17. Combined therapy with insulin plus oral agents: is there any advantage? An argument in favor.
Riddle MC
Diabetes Care; 2008 Feb; 31 Suppl 2():S125-30. PubMed ID: 18227472
[No Abstract] [Full Text] [Related]
18. UKPDS and the legacy effect.
Chalmers J; Cooper ME
N Engl J Med; 2008 Oct; 359(15):1618-20. PubMed ID: 18843126
[No Abstract] [Full Text] [Related]
19. Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline Update From the American College of Physicians.
Qaseem A; Barry MJ; Humphrey LL; Forciea MA; ; Fitterman N; Horwitch C; Kansagara D; McLean RM; Wilt TJ
Ann Intern Med; 2017 Feb; 166(4):279-290. PubMed ID: 28055075
[TBL] [Abstract][Full Text] [Related]
20. The continuing legacy of the United Kingdom Prospective Diabetes Study.
Davis TM; Colagiuri S;
Med J Aust; 2004 Feb; 180(3):104-5. PubMed ID: 14748669
[No Abstract] [Full Text] [Related]
[Next] [New Search]
